238 related articles for article (PubMed ID: 18035682)
21. Diagnostic strategies for unknown primary cancer.
Varadhachary GR; Abbruzzese JL; Lenzi R
Cancer; 2004 May; 100(9):1776-85. PubMed ID: 15112256
[TBL] [Abstract][Full Text] [Related]
22. TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
Zhang PJ; Gao HG; Pasha TL; Litzky L; Livolsi VA
Int J Gynecol Pathol; 2009 Jan; 28(1):10-8. PubMed ID: 19047914
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic and therapeutic management of cancer of an unknown primary.
Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
[TBL] [Abstract][Full Text] [Related]
24. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
25. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
[TBL] [Abstract][Full Text] [Related]
26. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors.
Cao D; Humphrey PA; Allan RW
Cancer; 2009 Jun; 115(12):2640-51. PubMed ID: 19365862
[TBL] [Abstract][Full Text] [Related]
27. Metastasis of unknown origin.
Perchalski JE; Hall KL; Dewar MA
Prim Care; 1992 Dec; 19(4):747-57. PubMed ID: 1465485
[TBL] [Abstract][Full Text] [Related]
28. Treatment for patients with unknown primary cancer and favorable prognostic factors.
Hainsworth JD; Fizazi K
Semin Oncol; 2009 Feb; 36(1):44-51. PubMed ID: 19179187
[TBL] [Abstract][Full Text] [Related]
29. Pathologic evaluation of unknown primary cancer.
Oien KA
Semin Oncol; 2009 Feb; 36(1):8-37. PubMed ID: 19179185
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site.
Ilson DH; Motzer RJ; Rodriguez E; Chaganti RS; Bosl GJ
Semin Oncol; 1993 Jun; 20(3):229-37. PubMed ID: 8503018
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling of non-small-cell lung cancer.
Lacroix L; Commo F; Soria JC
Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
Horlings HM; van Laar RK; Kerst JM; Helgason HH; Wesseling J; van der Hoeven JJ; Warmoes MO; Floore A; Witteveen A; Lahti-Domenici J; Glas AM; Van't Veer LJ; de Jong D
J Clin Oncol; 2008 Sep; 26(27):4435-41. PubMed ID: 18802156
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of metastatic neoplasms with unknown primary.
Bochtler T; Löffler H; Krämer A
Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
[TBL] [Abstract][Full Text] [Related]
34. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
Bellizzi AM
Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
[TBL] [Abstract][Full Text] [Related]
35. Merkel cell carcinoma of the inguinal lymph node with an unknown primary site.
Kim EJ; Kim HS; Kim HO; Jung CK; Ko YH; Kim TH; Park YM
J Dermatol; 2009 Mar; 36(3):170-3. PubMed ID: 19335694
[TBL] [Abstract][Full Text] [Related]
36. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
37. [The pathological practice for metastatic carcinoma of unknown primary-the current status and future prospect].
Watanabe M
Gan To Kagaku Ryoho; 2009 Jun; 36(6):910-4. PubMed ID: 19542710
[TBL] [Abstract][Full Text] [Related]
38. Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck.
Serrano MF; El-Mofty SK; Gnepp DR; Lewis JS
Hum Pathol; 2008 Apr; 39(4):591-8. PubMed ID: 18284937
[TBL] [Abstract][Full Text] [Related]
39. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.
Kamposioras K; Pentheroudakis G; Pavlidis N
Eur J Clin Invest; 2013 May; 43(5):491-500. PubMed ID: 23480555
[TBL] [Abstract][Full Text] [Related]
40. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
